Published in World J Gastroenterol on December 14, 2008
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology (2011) 2.63
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene (2013) 1.55
Cholangiocarcinoma: molecular pathways and therapeutic opportunities. Semin Liver Dis (2014) 1.28
Genetic profiling of intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol (2012) 1.14
Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms. Clin Gastroenterol Hepatol (2009) 1.13
The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer. Dis Model Mech (2013) 1.01
New insights on cholangiocarcinoma. World J Gastrointest Oncol (2010) 0.94
The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice. J Hepatol (2012) 0.92
EGFR Signaling in Liver Diseases. Int J Mol Sci (2015) 0.90
Patterns of chromosomal copy-number alterations in intrahepatic cholangiocarcinoma. BMC Cancer (2015) 0.87
High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT/p70S6K. World J Gastroenterol (2010) 0.85
A perspective on molecular therapy in cholangiocarcinoma: present status and future directions. Hepat Oncol (2014) 0.81
Accumulation of neoplastic traits prior to spontaneous in vitro transformation of rat cholangiocytes determines susceptibility to activated ErbB-2/Neu. Exp Mol Pathol (2010) 0.81
Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab. J Gastroenterol (2014) 0.80
Emerging Molecular Therapeutic Targets for Cholangiocarcinoma. J Hepatol (2017) 0.78
Integrative analysis of transcriptional regulatory network and copy number variation in intrahepatic cholangiocarcinoma. PLoS One (2014) 0.76
Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications. Oncotarget (2016) 0.75
Expression of COX-2 and HER-2 in colorectal cancer and their correlation. World J Gastroenterol (2015) 0.75
Expression and activation of EGFR and STAT3 during the multistage carcinogenesis of intrahepatic cholangiocarcinoma induced by 3'-methyl-4 dimethylaminoazobenzene in rats. J Toxicol Pathol (2015) 0.75
An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma. Int J Genomics (2015) 0.75
Molecular Markers in the Pathogenesis of Cholangiocarcinoma: Potential for Early Detection and Selection of Appropriate Treatment. Gastroenterology Res (2009) 0.75
Oncogenic role of rab escort protein 1 through EGFR and STAT3 pathway. Cell Death Dis (2017) 0.75
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer (2005) 16.73
Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer (2007) 14.84
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (2007) 10.60
Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med (2008) 6.82
Cholangiocarcinoma. Lancet (2005) 6.01
HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol (2001) 5.59
The epidemiology of cholangiocarcinoma. Semin Liver Dis (2004) 5.59
Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology (2001) 5.12
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol (2006) 4.91
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res (2007) 4.45
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene (2002) 3.87
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell (2006) 3.73
Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci (2007) 3.52
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer (2007) 3.32
Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol (2006) 3.31
Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther (2005) 3.28
Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology (2005) 3.24
The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell (2003) 3.20
Cholangiocarcinoma. Gastroenterology (2005) 3.15
Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res (2004) 3.13
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene (2000) 3.12
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene (2005) 3.05
Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Mol Syst Biol (2006) 3.01
ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest (2007) 2.78
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol (2005) 2.77
Cell surface-associated mucins in signal transduction. Trends Cell Biol (2006) 2.58
Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology (2005) 2.56
Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell (2004) 2.53
Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem (2000) 2.46
ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol (2006) 2.39
Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy. Am J Gastroenterol (2007) 2.39
Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med (Maywood) (2006) 2.33
Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res (2006) 2.21
Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol (2006) 2.19
Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res (2007) 2.14
Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. Proc Natl Acad Sci U S A (2007) 2.10
Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer (2007) 2.09
Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature (1998) 2.08
The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun (2004) 2.05
Cholangiocarcinoma: current concepts and insights. Hepatology (2003) 1.96
EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res (2006) 1.85
Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer (2006) 1.83
Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res (2008) 1.82
Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol (2004) 1.80
Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res (2006) 1.80
Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology (2005) 1.78
A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev (2006) 1.76
MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90. Oncogene (2006) 1.75
Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer Res (2008) 1.69
Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes. J Hepatol (2005) 1.69
Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology (2006) 1.68
Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy. Cancer Res (2007) 1.61
EGFR targeting of solid tumors. Cancer Control (2007) 1.61
Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J Hepatobiliary Pancreat Surg (2003) 1.59
The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets (2005) 1.59
A histopathologic study of 102 cases of intrahepatic cholangiocarcinoma: histologic classification and modes of spreading. Hum Pathol (1988) 1.56
Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer (2006) 1.55
ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology (2002) 1.54
A novel "patient-like" model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines. Hepatology (2008) 1.53
Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol (2005) 1.52
Cell signaling through membrane mucins. Bioessays (2003) 1.51
Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer (2004) 1.51
Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer (2007) 1.51
Targeting the EGFR pathway for cancer therapy. Curr Med Chem (2006) 1.48
Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int J Cancer (2006) 1.48
Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res (2003) 1.48
Bile acids activate EGF receptor via a TGF-alpha-dependent mechanism in human cholangiocyte cell lines. Am J Physiol Gastrointest Liver Physiol (2003) 1.48
Retracted Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J Cell Physiol (2006) 1.46
Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study. Int J Cancer (2007) 1.46
ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium. J Mol Cell Cardiol (2008) 1.46
FDA drug approval summary: panitumumab (Vectibix). Oncologist (2007) 1.44
Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res (2006) 1.44
Genome-wide analysis of gene expression in human intrahepatic cholangiocarcinoma. Hepatology (2005) 1.43
MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. Hepatology (2004) 1.43
Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies. Cancer Res (2007) 1.41
Thioacetamide-induced intestinal-type cholangiocarcinoma in rat: an animal model recapitulating the multi-stage progression of human cholangiocarcinoma. Carcinogenesis (2003) 1.40
Biliary papillary neoplasm of the liver. Histol Histopathol (2002) 1.38
MUC1 is a novel regulator of ErbB1 receptor trafficking. Oncogene (2006) 1.38
Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. Cancer Res (2002) 1.37
Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein. Mol Cancer Res (2003) 1.34
Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann Surg (1998) 1.32
Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene (1999) 1.31
The mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3. J Biol Chem (2006) 1.31
Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology (2002) 1.31
Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. J Cancer Res Clin Oncol (2005) 1.30
Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma. Hepatology (1999) 1.30
Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors. FASEB J (2003) 1.29
Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Hum Pathol (1998) 1.29
Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance. Oncol Rep (2006) 1.28
Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother (2006) 1.28
Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha. Mol Cancer (2007) 1.27
erbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer. Gastroenterology (2005) 1.26
HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion. Mol Biol Cell (2004) 1.26
Targeting ErbB receptor signaling: a pan-ErbB approach to cancer. Mol Cancer Ther (2004) 1.25
Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res (2001) 1.25